| Date | Time | Source | |
| 09/18/2024 | 6:59AM | BW | New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More than eight years of DAYBREAK data confirm established safety profile of Zeposia, with rates of treatment-emergent adverse events... More...>> |
| 09/15/2024 | 8:55AM | BW | Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) of patients treated with Opdivo plus Yervoy were alive; a decade ago, this patient population faced a survival rate of around 25% after... More...>> |
| 09/12/2024 | 6:59AM | BW | Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are... More...>> |
| 09/10/2024 | 5:45PM | BW | Bristol Myers Squibb Announces Dividend
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024. In addition... More...>> |
| 09/09/2024 | 6:59AM | BW | Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Data from proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as first-line treatment for stage IV or recurrent NSCLC; BMS initiating Phase 3 RELATIVITY-1093 trial Ten-year follow-up data from CheckMate -067 showed continued durable, long-term... More...>> |
| 09/06/2024 | 7:00AM | BW | Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
With cancer patients top of mind, teams of Bristol Myers Squibb (NYSE: BMY) employees will relay Coast 2 Coast 4 Cancer (C2C4C) this year and cycle from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research. Since the ride’s inception in 2014, Bristol Myers Squibb... More...>> |
| 09/01/2024 | 3:33AM | BW | Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Cumulative analysis of data up to 3.5 years from EXPLORER-LTE showed consistent and sustained improvements in echocardiographic measures and symptoms, with no new safety signals observed CAMZYOS is the first and only approved cardiac myosin inhibitor that targets the source of symptomatic obstructive hypertrophic cardiomyopathy... More...>> |
| 08/27/2024 | 6:59AM | BW | Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in September 2024. Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan... More...>> |
| 08/26/2024 | 6:59AM | BW | Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
New analyses, including presentations on CAMZYOS® (mavacamten), ELIQUIS® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases Not intended for UK and Ireland audiences Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across... More...>> |
| 08/23/2024 | 8:20AM | IHMARKETNEWS | Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%
Uber Technologies (NYSE:UBER), General Motors (NYSE:GM) – Cruise, a self-driving car subsidiary of General Motors, has partnered with Uber to offer rides in its robotaxis on the platform starting next year. This collaboration comes as Cruise recovers from an accident in San Francisco, resuming testing with safety... More...>> |
| 08/21/2024 | 6:59AM | BW | Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of lenvatinib or sorafenib in this patient population The U.S. Food and Drug Administration assigned a target action date of April 21, 2025 Bristol... More...>> |
| 08/19/2024 | 6:59AM | BW | European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Application based on the TRANSCEND FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile Breyanzi also received approval in Japan for the treatment of relapsed or refractory follicular lymphoma (FL) after one prior line of systemic therapy in patients with high-risk... More...>> |
| 07/30/2024 | 6:00AM | IHMARKETNEWS | Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots
Toyota Motor (NYSE:TM) – Toyota’s global production fell 12.9% in June to 795,862 vehicles, marking the fifth consecutive month of decline. The automaker faced certification issues in Japan and intense price competition in China, contributing to significant reductions both domestically and internationally... More...>> |
| 07/26/2024 | 6:59AM | BW | Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were $12.2 Billion, increasing 9% (+11% Adjusting for Foreign Exchange) Growth Portfolio Revenues were $5.6 Billion, increasing 18% (+21% Adjusting for Foreign Exchange) GAAP EPS... More...>> |
| 07/26/2024 | 6:08AM | IHMARKETNEWS | U.S. Index Futures Point to Higher Open, Oil Prices Down
U.S. index futures point to a higher open in pre-market trading on Friday, with investors preparing for the Federal Reserve’s preferred inflation report. Despite pre-market optimism, the week promises to be negative, with the S&P 500 and Nasdaq facing sharp losses due to sell-offs in big tech and a shift to smaller... More...>> |
| 07/26/2024 | 5:57AM | IHMARKETNEWS | Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates
Dexcom (NASDAQ:DXCM) – The continuous glucose monitor company reported second-quarter revenue of $1 billion, below the estimate of $1.04 billion, according to LSEG. Adjusted earnings per share of 43 cents were better than the estimated 39 cents. However, Dexcom issued a reduced annual revenue forecast of $4 billion... More...>> |
| 07/19/2024 | 6:59AM | BW | Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
The Application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its Type... More...>> |
| 07/08/2024 | 6:59AM | BW | Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS. Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer and Head of Research, will take part in a fireside chat on Monday, July 15, 2024. He will answer questions... More...>> |
| 06/21/2024 | 7:30PM | BW | Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients with locally advanced or metastatic CRC harboring a KRASG12C mutation1 Second FDA approval for KRAZATI - reinforcing its potential across tumor types Bristol... More...>> |
| 06/21/2024 | 6:59AM | BW | European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics and efficacy vs. its intravenous formulation Application seeks approval for subcutaneous nivolumab formulation to treat multiple Opdivo adult solid... More...>> |